Why isn't there a one-size-fits-all approach for relapsed/refractory acute myeloid leukemia? Insights into different variables for decision-making

Publication date: Available online 11 January 2021Source: Best Practice &Research Clinical HaematologyAuthor(s): Ehab L. Atallah
Source: Best Practice and Research Clinical Haematology - Category: Hematology Source Type: research

Related Links:

Publication date: Available online 8 October 2020Source: Hematology/Oncology and Stem Cell TherapyAuthor(s): Ram Vasudevan Nampoothiri, Shiyi Chen, Ivan Pasic, Zeyad Al-Shaibani, Wilson Lam, Fotios V. Michelis, Dennis Dong Hwan Kim, Auro Viswabandya, Armin Gerbitz, Jeffrey Howard Lipton, Rajat Kumar, Jonas Mattsson, Arjun Datt Law
Source: Hematology Oncology and Stem Cell Therapy - Category: Cancer & Oncology Source Type: research
ConclusionAround 40% of patients had fever at the time of presentation, and 31% had documented infections. Baseline infections led to increase in induction mortality. We would like to propose that infection at baseline is to be considered as one of the potential variables in the predictive scoring system for induction mortality in developing countries.
Source: Supportive Care in Cancer - Category: Cancer & Oncology Source Type: research
FRIDAY, Oct. 9, 2020 -- Male sex, older age at diagnosis, White race, and having acute myeloid leukemia are risk factors associated with suicide among patients with leukemia, according to a study published online Oct. 6 in Cancer Medicine. Haohui...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
ovsek Janus kinase (JAK) inhibition forms the cornerstone of the treatment of myelofibrosis (MF), and the JAK inhibitor ruxolitinib is often used as a second-line agent in patients with polycythemia vera (PV) who fail hydroxyurea (HU). In addition, ruxolitinib continues to be studied in patients with essential thrombocythemia (ET). The benefits of JAK inhibition in terms of splenomegaly and symptoms in patients with MF are undeniable, and ruxolitinib prolongs the survival of persons with higher risk MF. Despite this, however, “disease-modifying” effects of JAK inhibitors in MF, i.e., bone marrow fib...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
THURSDAY, Oct. 8, 2020 -- For patients with acute myeloid leukemia (AML), achieving measurable residual disease (MRD) negativity is associated with improved survival, according to a review and meta-analysis published online Oct. 8 in JAMA...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
Interview with Farhad Ravandi, MD, author of Association of Measurable Residual Disease With Survival Outcomes in Patients With Acute Myeloid Leukemia: A Systematic Review and Meta-analysis
Source: JAMA Specialty Journals Author Interviews - Category: General Medicine Authors: Source Type: podcasts
Graft-versus-host disease (GVHD) is a major complication of bone marrow transplantation. Polymyositis with myonecrosis is a rare manifestation of GVHD. Here, we report the case of a 32-year-old man with acute myeloid leukemia who developed GVHD after transplant. He subsequently developed polymyositis, which was diagnosed on PET/CT and confirmed on pathology. Treatment with corticosteroids resulted in the resolution of the symptoms. Abnormal muscular FDG uptake resolved on the follow-up PET/CT.
Source: Clinical Nuclear Medicine - Category: Nuclear Medicine Tags: Interesting Images Source Type: research
Journal of Natural ProductsDOI: 10.1021/acs.jnatprod.0c00516
Source: Journal of Natural Products - Category: Biochemistry Authors: Source Type: research
Donor cell (DC) leukemia is a rare cause of relapse after allogeneic hematopoietic cell transplantation and usually presents as acute myeloid leukemia. Uncommonly, other DC ‐derived hematologic malignancies can occur and usually have a poor prognosis. AbstractDonor cell leukemia is a very rare cause of relapse after allogeneic hematopoietic cell transplantation (alloHCT). Herein, we describe an unprecedented case of donor cell ‐derived chronic myelomonocytic leukemia (CMML) presenting seven years after a 51‐year‐old man received a matched‐related alloHCT from his 59‐year‐old brother for T‐cell acute lymphoblastic leukemia.
Source: Clinical Case Reports - Category: General Medicine Authors: Tags: CASE REPORT Source Type: research
ConclusionVery long term survivors after AA are those with stable hematopoietic recovery.
Source: Annals of Hematology - Category: Hematology Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Hematology | Leukemia